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Leishmaniasis is a protozoan parasitic disease endemic to the tropical and subtropical regions of the world, with three major
clinical forms, self-healing cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), and visceral leishmaniasis (VL).
Drug treatments are expensive and often result in the development of drug resistance. No vaccine is available against leishmaniasis.
Subunit Leishmania vaccine immunization in animal models has shown some eﬃcacy but little or none in humans. However,
individuals who recover from natural infection are protected from reinfection and develop life-long protection, suggesting that
infection may be a prerequisite for immunological memory. Thus, genetically altered live-attenuated parasites with controlled
infectivity could achieve such memory. In this paper, we discuss development and characteristics of genetically altered, live-
attenuated Leishmania donovani parasites and their possible use as vaccine candidates against VL. In addition, we discuss the
challenges and other considerations in the use of live-attenuated parasites.
1.Introduction
Leishmaniasis is caused by protozoan parasites of the
genus Leishmania of the family Trypanosomatidae and is
transmitted by the sand ﬂy vector. It infects about 12 million
individuals globally in tropical and subtropical regions,
with ∼2 million new clinical cases (0.5 million visceral
leishmaniasis (VL) and 1.5 million cutaneous leishmaniasis
(CL)) reported annually with an estimated death toll of
∼50,000 persons/year [1]. The three major clinical forms of
leishmaniasis, VL, CL, and MCL are the result of infection by
diﬀerent species of the parasite and the immune response of
the host. VL, fatal if not treated, is caused by L. donovani, L.
infantum,andL.chagasi [2,3].Morethan90%ofthevisceral
cases in the world are reported from Bangladesh, Brazil,
India, and Sudan. Most aﬀected patients (70%) are children
under 15 years of age who already suﬀer from concurrent
malnutrition and other secondary illnesses. The major
clinical symptoms for VL are characterized by prolonged
and irregular fever, splenomegaly, and hepatomegaly [3]. CL
causeslesionsthatareself-healingandarecausedbyL.major,
L.tropica,orL.aethiopicaintheoldworldandbyL.mexicana
or L. braziliensis complex in the new world [4]. MCL is
potentially life threatening and aﬀects the mucosal region of
infected individuals, typically seen in the Central and South
America and caused by L. braziliensis, L. amazonensis, L.
panamensis, and L. guyanensis [3].
In the Leishmania life cycle, motile promastigote forms
thatresideinthegutofthesandﬂyvectoraretransmittedtoa
mammalian host during a blood meal. Parasites are taken up
bytheneutrophilsthatareingestedbythehostmacrophages,
diﬀerentiate into the nonmotile amastigote form, and reside
and multiply in the phagolysosome compartment of the
macrophages. These two major life stages have been adapted
to in vitro culture for most Leishmania species allowing
manipulation of the genome and assessment of the altered
phenotypes in vitro and in vivo.2 Journal of Tropical Medicine
Themostsigniﬁcantpublichealtheﬀectsofleishmaniasis
are concentrated in developing countries. Dogs represent an
important reservoir for the parasite in Europe, the Middle
East, as well as Latin America. In the USA, even though
leishmaniasis is not endemic, infections can be observed in
pockets of the country, mainly in the southwest [5, 6]. In
addition, VL due to L. infantum was found in fox hounds
in the northeastern part of the USA and transmission may
involve exposure to an insect vector, direct transmission,
or vertical transmission [7]. In addition, there have been
several documented cases of parasite transmission by blood
transfusion globally [8] and an outbreak of leishmaniasis
among US troops led to deferral from donating blood
for travel to Iraq in 2003 [9]. Studies in animal models,
such as hamsters and dogs show that Leishmania not only
survives blood-banking storage conditions, but also retains
its infectivity [10, 11]. This retention of infectivity in blood
raises the possibility of spread of disease from asymptomatic
individuals through transfusion to healthy individuals in
areas where the sand ﬂy vector is absent.
Currently, the only treatment for leishmaniasis is drug
treatment. However, either prolonged use or ineﬃcient drug
therapy has resulted in drug resistance. Currently, more than
60% of the clinical cases are resistant to the ﬁrst line drug,
antimony [12]. There is concern about the possibility of
development of resistance to the new oral drug miltefosine
in the near future as there are already reports of relapse
among miltefosine treated cases [13]. In addition, about
50% of Sudanese and 5–10% of Indian kala azar patients
within months after successful treatment develop post-kala-
azar dermal leishmaniasis (PKDL) [14]. PKDL is a condition
characterized by the appearance of diﬀuse lesions in the
skin that harbor the visceral parasite and is considered a
reservoir for transmission in these countries. There are no
vaccines available at present. Attempts to develop vaccines
for such parasitic agents such as heat killed, subunit, or DNA
vaccines have not resulted in a successful vaccine candidate
that could be applicable to humans [15–17]. However,
past experience has revealed that individuals who recover
from Leishmania infection develop a long lasting protection
from future infections suggesting that a successful vaccine
candidate needs to cause a controlled infection that evokes
a protective immunity. Experience from other pathogens has
suggested that a live-attenuated parasite vaccine could fulﬁll
such requirements [18, 19]. Hence, in this paper we have
focused on current knowledge about the (a) immunology
of leishmaniasis, (b) need for and development of live-
attenuated Leishmania parasites as vaccine candidates, (c)
the safety challenges such parasites present, (d) the type
of immune responses generated by such parasites that
are protective, (e) experimental animal models for testing
vaccines, and (f) routes of administration and mode of
virulent challenge for vaccinated animals. Recently, various
review articles have been published discussing the role of
genetically altered Leishmania as vaccine candidates [3, 16,
17, 20–23]. In this paper we have limited our scope to
genetically altered L. donovani parasites and their use as
vaccine candidates.
2. Immunology of Leishmaniasis
Immunity to leishmaniasis is mediated by both arms of
mammalian cellular immune system; innate (by neutrophils,
macrophages, and dendritic cells) and adaptive (T cells)
responses [20]. The sand ﬂy bite causes minimal tissue
damage that promotes recruitment of neutrophils to the site
of injury as a primary immune defense mechanism of the
host [24, 25]. However, regardless of Leishmania species,
these neutrophils are the primary target of this parasite.
Despite the harsh intracellular environment, parasites can
survive for a time period, and eventually these parasitized
neutrophils or viable parasites are engulfed by macrophages
or dendritic cells. Leishmania can survive and replicate
inside macrophages by modulating the normal antimicrobial
machinery as well as increasing the host cell membrane
ﬂuidity and disrupting lipid rafts, which in turn aﬀects the
antigen presentation capability of host APCs [26]. These
parasitized APCs then interact with T cells to stimulate
cytokines, and in this whole process, several cytokines and
chemokines are involved. In this way, Leishmania starts to
hijack the whole immune system for its survival [27].
In leishmaniasis, host defense against intracellular Leish-
mania is cell mediated, which involves Th1 responses due to
T-cells primed primarily by dendritic and macrophage cells
producing IL-12 [28–31]. A clear dichotomy between Th1-
mediated protection (mediated by major cytokines IFNγ,I L -
2, TNF) and Th2-mediated disease progression (mediated
by major cytokines IL-10, IL-4) has been demonstrated in
mice against cutaneous leishmaniasis [21, 32]. However, this
Th1/Th2 dichotomy is not as clear in visceral infection of
mice and even less in human visceral leishmaniasis [33]. The
immuneresponseandpathologyofvisceralleishmaniasisare
complex, involving a number of genetic and cellular factors
in the process of susceptibility or resistance to parasites [34].
2.1. Nonhealing Response. Susceptibility to visceral leishma-
niasis is correlated with the presence of a Th2 response [33].
L. donovani infections stimulate expression of Th2 associated
cytokines (IL-10, IL-4, IL-5, and IL-13). Further, elevated
levels of IL-10 in serum and enhanced levels of IL-10mRNA
expression in lesion tissue are a direct indication of severe
visceral leishmaniasis in mice and humans [35–38]. IL-10
plays a crucial role in the establishment and maintenance
of Th2-dependent immune responses by suppressing Th1-
dependent cell-mediated immunity in CL [39, 40]. In the
murine VL model, IL-10 directly inhibits the antimicrobial
machinery of macrophages by modulating normal signal
transduction mechanisms [41]. IL-10 inhibits killing of
amastigotes by downregulating the production of TNF-
α and nitric oxide by macrophages and dendritic cells
and thereby strongly impairs their antimicrobial activity
[41, 42]. IL-10 also inhibits the production of IFNγ,o n e
of the major proinﬂammatory cytokines [43]. However,
in visceral leishmaniasis, it has been suggested that the
impaired function of cellular immunity that correlates with
progression of active disease may be due to the inhibitory
eﬀects of IL-10 independent of the IFNγ level [44].Journal of Tropical Medicine 3
IL-10, in addition, is also a regulatory cytokine
mainly secreted by T cells, B cells, macrophages, den-
dritic cells, and keratinocytes [39, 45]. In experimental
cutaneous leishmaniasis in mice, natural T regulatory cells
(CD4+CD25+FoxP3+) are a major source of IL-10, and
these cells are crucial for maintenance of parasite per-
sistence [46]. However, in experimental VL in mice [47]
and in human visceral leishmaniasis [37], IL-10 comes
from non-T reg cells (CD4+CD25−FoxP3−), indicating that
therapeutic approaches require Leishmania species-speciﬁc
understanding of the immune response. IL-4 has generally
beenconsideredaTh2cytokinethathelpsintheproliferation
of the Th2 cell population and consequently a signiﬁcant
downregulator of Th1 cell response [48, 49] .I t sr o l ei n
CL is well deﬁned but not in VL [32]. For example, the
parasite burden of L. donovani in infected IL-4−/− and IL-
4+/+ BALB/c mice was similar [50]. However, IL-4 null
mice are more susceptible to visceral leishmaniasis than their
wild-type counter parts after drug therapy [50], suggesting
that IL-4 is necessary for eﬀective chemotherapy in visceral
leishmaniasis [50].
2.2. Healing Response. In VL (both in murine and human),
resolution of infection depends on the production of Th1
cytokines [21, 31, 38, 51–54]. Production of IL-12 by antigen
presentingcellsandIFNγ byTcellsarecrucialforcontrolling
the parasite growth and development of host immunity
[51, 55]. There seems to be a dichotomy in the role of IL-
10 in VL. On one side, IL-10 suppresses host immunity and
helpsparasitesurvival,ontheﬂipside,IL-10alsoprotectsthe
host from tissue damage by exaggerated inﬂammation [56].
Recent ﬁndings suggest that some IFNγ producing cells are
a crucial source of IL-10, which act as a negative feedback
mechanism to control tissue damage [57, 58]. A study with
VL patient splenic T cells showed elevated expression of both
IFNγ and IL-10 [37] suggesting that at least some cells are
producing both cytokines as part of a strong inﬂammatory
response and limiting the tissue damage by a feedback
control mechanism [33]. TNFα also shares a signiﬁcant
role in resistance because TNFα−/− mice readily succumb
to infection with Leishmania species [59, 60]. In addition,
TNFα was also shown to stimulate the action of IFNγ in the
induction of nitric oxide production in macrophages to kill
the parasite [61]. Chemokines also play an important role in
killing parasites from host cells [51, 62–64]. Antileishmanial
activity of chemokines has been demonstrated in both in
vitro and in vivo infections in murine VL by induction of
respiratory burst as well as by induction of Th1 cytokines
[65, 66]. Another CD4+ T-cell lineage called Th17 cells was
initially characterized as producing IL-17 family cytokines
[67]. They are proinﬂammatory cytokines that stimulate the
production of IL-6, TNFα, and chemokines. A recent study
suggests that L. donovani strongly induced IL-17 and IL-22
in human PBMCs and enhanced secretion of these cytokines
correlated with protection [68].
In addition to CD4+ T cells, the signiﬁcant role of CD8+
cytotoxic T cells in the control of experimental CL and VL
has been described [69]. In murine experimental VL, control
of parasite multiplication and leishmaniacidal activity are
both associated with development of a granuloma in the
liver, which requires both CD4 and CD8 T cells as well as
IL-12, IFNγ, and IL-2 [30, 55, 70–73]. On the other hand,
B cell deﬁcient animals showing resistance to Leishmania
infectionandincreasedlevelsofIgGinhumanandcanineVL
(with few recent reports showing exceptions in these hosts)
suggest that antibodies are not necessary for protection in
the absence of an appropriate cellular response [22]. Thus,
in addition to the protective T-cell response, the role of
other T-cell subsets, including regulatory T and Th17 cells in
eithersusceptibilityorresistancetoexperimentalandhuman
visceral leishmaniasis, has not been ruled out and requires
detailed investigations to help in vaccine designs.
3.TheNeedforaGeneticallyAltered
Live-AttenuatedVaccine againstVL
Drug treatment requires long-term medication, which is
expensive and highly toxic and often leads to resistance.
Hence, vaccine strategies to combat leishmaniasis are very
attractive. Though recombinant protein and DNA vaccines
are under investigation, and in the past whole cell parasite
lysates, heat killed parasites with or without adjuvants were
used, a promising alternative is to develop live-attenuated
parasite vaccines by genetic manipulation of genes that
are necessary for virulence [22]. Moreover, live-attenuated
pathogens have been used successfully as vaccine candidates
against various viral and bacterial pathogens [19, 74]. In
addition, the argument to use live-attenuated parasites as
vaccine candidates becomes compelling based on the follow-
ing facts: (a) complete Leishmania cDNA expression library
injected into mice was more protective than any subpools of
thelibraryplasmidsorasubunit,reinforcingtheideathatthe
wholeparasitemakesthebestvaccine[15];(b)thecutaneous
leishmanization practiced in the Middle East and Uzbekistan
or the persistence of few parasites in the body even after
cure protected individuals from reinfection [23]; (c) healing
fromnaturalordeliberateinfectionwithL.major leadstothe
generation of more eﬀective immunity against rechallenge in
mice than vaccination with either killed parasites or deﬁned
leishmanial antigens that generally induce only short-term
protection [75]; (d) in the past, researchers have developed
attenuated strains by passaging through long-term culture,
chemical mutagenesis, γ-irradiated, parasite culture under
high drug pressure, and so forth [76–78]. Immunization
with such attenuated strains showed a signiﬁcant amount
of protection upon virulent challenge in the mouse model,
however, concerns about nonspeciﬁc attenuation that could
result in reversion to infectivity of such strains does not
make this a viable strategy. Further, nonspeciﬁc attenuation
can lead to loss of protective immunity either by simply
losing virulence or failure to establish subclinical infection.
Therefore, the best alternate strategy would be to use
“genetically deﬁned live-attenuated” parasites. In the post
genomic era with the help of Leishmania species-speciﬁc
genomes, we can target a critical gene(s) that are responsible
forsurvivalinsidemacrophages,anddeletionofsuchspeciﬁc4 Journal of Tropical Medicine
gene(s) by homologous recombination allows the selection
ofparasiteslackingthosecriticalgenesforvirulence.Further,
we expect that immunization with such attenuated parasites
will render protection against virulent infection by eliciting
parasite-speciﬁc immune response in the host just like after
recovering from natural infection. Most importantly, the
live-attenuated organisms will have the complete antigen
spectrum like their wild-type counterparts, which may result
in a robust immunity as compared to subunit vaccines that
cannot provide the complete repertoire of antigens. Finally,
by its nature, the attenuated parasite will persist in the
host for a certain period of time providing the immune
system persistent antigens that may allow the generation
of antigen-speciﬁc memory cells that can be mobilized
to provide a protective response immediately following
subsequent infection. All of these features put together
make a compelling argument that the genetically deﬁned
attenuated parasite could be an alternative approach for a
vaccine against leishmaniasis, including for VL.
4.Development andTesting ofGenetically
Altered Live-Attenuated Vaccine Candidates
againstLeishmaniasis
Several targeted gene deletions have been carried out to
develop Leishmania-attenuated vaccine strains. Among the
vaccine candidates developed for CL, L. major dihydrofolate
reductase thymidylate synthase (dhfr-ts-) knockout parasites
protect mice [79] but not rhesus monkeys [80]. L. major
deﬁcient in surface and secreted phosphoglycans (lpg2−),
although unable to survive in sand ﬂies and macrophages,
retained the ability to persist indeﬁnitely in mice and
conferred protection against virulent challenge, even in the
absence of a strong Th1 response [81, 82]. However, lpg2−/−
parasites,overtime,unexpectedly,regainedvirulence[83].L.
major deleted for phosphomannomutase (PMM) protected
mice, despite no increase in either eﬀector or memory
response [84]. Additionally, L. mexicana that also causes
CL, deﬁcient in cysteine proteinase genes (Δcpa and Δcpb),
conferred protection in mice and hamsters against homol-
ogous challenge [85, 86]. Among the vaccination studies in
VL (Table 1), mice immunized with a L. donovani strain
deleted for biopterin transporter (BT1) were also similarly
protected from virulent challenge [87]. Recent attempts
usingpartialknockoutparasitesfortheA2-A2relgenecluster
in L. donovani [88] and SIR2 gene in L. infantum [89]a s
immunogens induced protection against virulent challenge
in BALB/c mice. However, such mutants cannot be used
as vaccine candidates, because they still carry wild type
allele/s and could cause disease. There were also eﬀorts to
enhance the vaccine safety by including drug sensitive L.
major mutants with suicide genes for controlled infection
[90, 91]. Hence, these experiments, despite limitations with
most of the mutant strains, demonstrate the potential as
well as the pitfalls of generating live-attenuated vaccines by
targeted gene disruptions. Hence, it is critical to develop
attenuated lines through complete gene knockouts that
generate organisms either with controlled infectivity that
persists for a long time or parasites that persists for a brief
duration and are eventually eliminated by the host immune
system, thereby inducing eﬀective immunity without clinical
disease or the risk of reactivation. Towards this concept, we
have developed several L. donovani mutant parasites, which
lack virulence-speciﬁc genes. We developed a L. donovani
mutant (LdCen−/−) deleted for the “centrin” gene. Centrin
is a growth regulating gene in the protozoan parasites Leish-
mania [92], Trypanosoma [93]a n dPlasmodium [94], and
higher eukaryotes [95]. LdCen−/− is speciﬁcally attenuated at
the amastigote stage and not as the promastigote [96]. The
mutant Leishmania amastigotes showed cytokinesis arrest in
the cell cycle and persisted for a short duration in animals
(mice and hamsters) or ex vivo in human macrophages
and were eventually cleared [53]. In the animal studies,
this attenuated parasite was found to be safe and protective
in mice and hamsters against virulent challenge [53]. We
also developed L. donovani mutant (Ldp27−/−) deleted for
the “p27”g e n e .Leishmania donovani 27kDa mitochondrial
inner membrane protein preferentially expressed in the
amastigote stage is essential component of cytochrome c
oxidase complex involved in oxidative phosphorylation [97].
The Ldp27−/− cell line is attenuated for infection of mice
[97] and is currently being evaluated for its potential as a
vaccinecandidate.Takentogethertheexamplesofgenetically
altered parasites described above provide opportunities for
live-attenuated vaccine candidates to be evaluated in pre-
clinical and clinical conditions. However, there are various
challenges to be addressed before such vaccine candidates
become a reality.
5. Challenges for the Use of Genetically
Altered Live-Attenuated Parasites as
Vaccine Candidates
5.1. Monitoring of Attenuation in the Live-Attenuated Vac-
cines to Ensure Safety. A main concern with live-attenuated
vaccines is the risk of reversion to a virulent parasite, since
these parasites are expanded to production levels and used
as vaccines to inoculate recipients. Hence, biochemical or
molecular indicators are needed to assess the genetic and
physiological traits of the organism to assess stability of the
attenuated parasites. Such indicators must be measurable
with an assay that is practical in the manufacturing setting
[99]. Therefore, in addition to monitoring the obvious pres-
ence or absence of the interested deleted gene, other genes,
that are uniquely altered in expression in such gene deleted
parasites, provide as indicators of attenuation. To date, there
are no known deﬁned indicators of attenuation for geneti-
cally altered parasites. Towards that end, our laboratory has
begun to identify such biochemical or molecular indicators.
For example, to assess genes whose expression patterns are
indicators of attenuation, the LdCen−/− line was compared
to wild-type by gene expression microarray [100, 101]. Two
genes, one coding for the mitochondrial inner membrane
protein (27kDa protein) and another coding for putative
Argininosuccinate Synthase, that normally express a higher
RNA level in the amastigote stage than in the promastigoteJournal of Tropical Medicine 5
Table 1: Genetically altered live-attenuated vaccine candidates against visceral leishmaniasis.
Parasite Characterization of attenuation Animal model Results of Immunization References
L. donovani Biopterin transporter gene deleted
parasite (BT1−/−) BALB/c mice Protective immunity,
antigen-speciﬁc IFNγ secretion [87]
L. tarentolae Nonpathogenic strain expressing
L. donovani A2 antigen BALB/c mice
Protective immunity against
L. infantum challenge, high IFNγ,
low IL-5
[98]





L. donovani and L. braziliensis
challenge. Increased IFNγ,I L - 2 ,a n d
TNF producing cells and
IFNγ/IL-10 ratio
[53]
L. infantum Silent information regulatory 2
single allele deletion (SIR2+/−) BALB/c mice Protective immunity, increased
antigen-speciﬁc IFNγ/IL-10 ratio [89]
L. donovani
Cytochrome c oxidase complex
component p27 gene deleted cell
line (Ldp27−/−)
BALB/c mice 12-week survival in host, initial
evidence of protective immunity
[97]a n dD e y ,
unpublished
stage of wild type cells, were found downregulated in their
RNA levels in LdCen−/− amastigote cells [99]. Northern blot
analysiswiththesetwogenesshowedthatLdCen−/−parasites,
recovered after ﬁve weeks of infection in mice, had the same
expression pattern as they had prior to infection. Therefore,
these two genes could be used as indicators of attenuation to
monitor the safety of the LdCen−/− cell line as it is developed
as a potential vaccine. However, further genetic evaluation
to identify any compensatory mutations that could arise also
will be an important aspect of any future such live vaccine
candidate development.
5.2. Selection of Parasite Culture Conditions That Are Safe
for Human Use. Live-attenuated parasite vaccines intended
for injection into healthy individuals will need to be man-
ufactured under strictly controlled conditions, that is, good
manufacturing practices (cGMP) avoiding ingredients that
could be hazardous for human use. One of the ingredients,
bovine serum, that the parasite normally needs for its
growth in culture, may not be suitable for human use. Even
though in most cases the use of serum from BSE-negative
animals is routine, there can be situations where it is not
practical. Therefore, we have tested culture conditions for
the genetically deﬁned, attenuated parasites in serum free
medium.
LdCen−/−,L d p 2 7 −/−,a n dLd1S2D, the parent wild-type
strain of these genetically altered parasites, were adapted to
growth in chemically deﬁned medium (serum free media:
SFM) [102]. SFM supported the growth of all tested L.
donovani parasites at rates comparable with those obtained
with serum-supplemented M199 medium (data not shown).
Moreover, growth in such medium did not aﬀect phenotypic
characteristics of the parasites. We did not observe any
diﬀerence in growth of mutant parasites compared to its
wild type counterpart (data not shown). Parasite viability
remained stable up to 6 days in culture (data not shown).
Taken together, these results demonstrate the feasibility of
cultivatingL. donovanipromastigotes in SFM and provide an
alternative to use of serum for growing such parasites.
5.3. Vaccine Candidate Transmissibility by the Sand Fly.
Another safety concern for genetically altered parasites to
be used as vaccine candidates is whether such parasites,
if taken up by sand ﬂies, are able to survive in the sand
ﬂy gut and develop into infectious metacylic cells. The
alterations made to date have been optimized for disrupting
survival as amastigotes, yet allowing propagation as cultured
promastigotes. Whether or not this will disrupt survival in
sand ﬂies cannot be predicted, but demonstration that the
attenuated parasites do not survive or diﬀerentiate in the
insect will be an important measure of safety blocking the
potential for genetic recombination [103] or transmission of
the vaccine strain. Preliminary studies from our laboratory
suggest that genetically modiﬁed parasites may not be able to
survive in the sand ﬂy gut (Dey et al., unpublished data).
6.Immunoprotection against VL by Genetically
AlteredLive-AttenuatedLeishmania Vaccines
In the literature, there are limited examples of genetically
modiﬁed L. donovani parasites that have been tested against
VL. The list of candidates is summarized in Table 1.F o l l o w -
ing are such examples. In our studies, mice immunized with
LdCen−/− cells showed clearance of virulent challenge para-
sites in 10 weeks after challenge, with signiﬁcantly reduced
parasite burden in the spleen and no parasites in the liver. In
contrast, high parasite loads were observed in the challenged
mice previously immunized with heat-killed parasites or
unimmunized [53]. Upon 10 week postvirulent challenge,
the immunized mice displayed among the CD4+ T-cell
population a signiﬁcant increase of single and multiple Th1
type cytokine (IFNγ, IL-2, and TNF) producing T cells and
increase in IFNγ/IL-10 ratio compared to nonimmunized
na¨ ıve mice infected with wild type parasites. The na¨ ıve chal-
lenged mice displayed a reduced Th1 response and increased
IL-10, a Th2 polarization accompanied by increased parasite
burden in the organs. LdCen−/− immunized mice in addition
showed increased IgG2a immunoglobulins and NO produc-
tion compared to control [53]. These features indicated a6 Journal of Tropical Medicine
protectiveTh1response.Protectionwasobserved,evenwhen
challenged 16weeks after immunization with LdCen−/−
parasites and in some cases even longer periods (24 week),
signifying a sustained immunity and suggesting generation
of a memory response. Thus, the immunity may remain
aftertheabsoluteclearanceofattenuatedparasitesdemanded
of a safe vaccine candidate. Protection by immunization
with LdCen−/− parasites was also seen in hamsters [53]. In
addition, we found that immunization with these mutant
cells also cross-protected mice against challenge with L.
braziliensis that causes mucocutaneous leishmaniasis (MCL)
[53] and against L. mexicana that causes cutaneous leishma-
niasis (CL) (unpublished data), indicating LdCen−/− to be a
safe and eﬀective vaccine candidate against VL, MCL, and
CL. We also have recently developed another live-attenuated
L. donovani parasite that lacks a gene that is part of the
cytochrome c oxidase complex and is necessary for oxidative
phosphorylation [97]. Preliminary data suggest that this
couldalsoserveasalive-attenuatedvaccinecandidatesimilar
to LdCen−/−.
Th1 polarization towards protection against VL was
also observed in animals after vaccination with other live-
attenuated parasites (Table 1). Elevated IFNγ to IL-10 ratio
with increased NO level and increase in both type 1
and 2IgG antibodies correlating with parasite elimination
was observed after L. infantum challenge in mice immu-
nized with SIR2+/− L. infantum [89]. BT1 null mutant L.
donovani parasites upon immunization in mice produced
signiﬁcant amounts of IFNγ correlating with protection
against virulent challenge [87]. Immunization of BALB/c
micewithnonpathogenicstrainofLeishmania(L.tarentolae)
expressing L. donovani A2 antigen resulted in protective Th1
type of protective immunity against L. infantum challenge
[98]. Finally, safety and eﬃcacy of the genetically altered
L. donovani live-attenuated candidate vaccines need to be
assessed in large animals as was done for other Leishmanias.
Generation and preservation of the immunological
memory seems to be the most important but least studied
aspect of antiparasitic vaccine development. In CL, the role
of memory cells has been well studied and suggests gener-
ation of both eﬀector (EM) and central memory (CM) T
cells during infection [75, 104]. After antigenic stimulation,
a few pathogen-speciﬁc EM T cells become CM T cells,
which live for longer periods of time and stay in secondary
lymphoid organs. Upon antigenic restimulation, CM cells
become EM T cells and mediate protection [105]. Mice
immunized with live-attenuated L. major parasites (DHFR
deletedparasite)showedsigniﬁcantprotectionuponvirulent
parasite challenge, even after 25 weeks of immunization
(in the absence of gene deleted parasites) and was due to
the presence of CM cells [104]. Similarly, mice immunized
with LdCen−/− vaccine candidate, that does not survive
beyond 5 weeks after injection in mice, but shows protection
when mice are challenged even 24 weeks after immunization
[53] suggests LdCen−/− parasites could be generating a
memory response that could be recalled upon challenge
as was shown by Zaph et al. [104]f o rL. major. On the
contrary, it is possible that protection by LdCen−/− parasites
is achieved by establishing a low-grade persistent infection
not detectable by current methods. This can be addressed
by immunosuppressing immunized mice and monitor for
parasite reemergence.
7. Other Considerations for Evaluation of
GeneticallyAlteredLive-AttenuatedVaccine
Candidates
7.1. Experimental Models to Test Vaccines. The relevance of
animal models is to understand the immunopathogenesis
andtodesign,formulate,andtestLeishmaniavaccines/drugs.
The models are expected to mimic the pathology and
immunologyobservedinhumansfollowinginoculationwith
Leishmania. Criteria for establishment of infection in the
animals are (i) susceptibility to infection, (ii) the age of
the animal, and (iii) mode of infection. For in vivo testing
of DNA, protein, or live parasite vaccines for VL, many
animals have served as hosts, namely, BALB/c mice and
Syrian golden hamster as primary screens, dogs as secondary
screen, and squirrel, vervet, and Indian langur monkeys as
tertiary screens [106–108]. Among such animals, the mouse
may not be an ideal model for VL because in most situations
the animals clear infection from both liver and spleen.
However, the mouse model is used for VL studies in order
to study the immune responses in the initial pathogenicity
period since there are abundant immunological reagents
available. Hence for VL, hamsters and nonhuman primates
are more valuable models because of their similarity to
human physiology and disease. The almost total lack of
immunological tools for these animals is a disadvantage and
it is not clear to what extent development or lack of immune
responses in such animals are comparable to human. Among
the nonhuman primates, African green monkeys were used
as model to test infectivity of Leishmania, namely, L. major
[109–111], L. aethiopica [112], L. donovani [113], and L.
infantum [113], both langur monkey and squirrel monkey
with L. donovani [114, 115], and owl monkey and marmoset
with L. braziliensis [116, 117]. Few live-attenuated vaccines
have been tested so far in mice/hamsters (Table 1). To our
knowledge, no testing of live-attenuated vaccines against
VL in non-human primates has been reported. However, a
few vaccine studies conducted in monkeys against CL will
provide insights in our understanding of vaccine studies
against VL. The dhfr-ts- L. major, although protecting mice
against CL, did not protect rhesus monkeys due to lack of
protectiveimmuneresponse[79,80].However,inananother
study, rhesus monkeys previously exposed to L. major,u p o n
reinfection with L. major metacyclic promastigotes, showed
reduced lesion compared to infection in na¨ ıve monkeys,
signifying the immune response to live cutaneous parasites
[118]. Limitations on the use of the dog or a monkey
model are stipulated by the limited availability of such
vaccine candidates in Leishmania e n d e m i ca r e a s .H e n c e ,
it is important to forge collaborations with experts in
nonendemic areas to address such questions.
Our recent studies [119] and studies by others [120–
124], with PBMC from Indian patients of VL, indicated
elevated serum levels of IFNγ, IL-10, and IL-6 during theJournal of Tropical Medicine 7
active disease, while TNF, IL-2, and IL-4 levels were minimal.
Direct infection of healthy human PBMC ex vivo with live L.
donovani parasites revealed elevated expression of IL-4 and
IFNγ in the host cells [125]. Similarly, IFNγ upregulation
was noticed in the PBMCs from nonexposed dogs after
cocultured with L. chagasi promastigotes ex vivo [126].
Additionally, exposure of human PBMCs to peptides from a
Leishmania surface antigen produced T cells that recognized
Leishmania-infected autologous macrophages [127]. Since
ethical reasons do not permit testing vaccine candidates
directlyinhumans,asapreclinicalevaluationofvaccines,the
ex vivo grown human cells can be infected with live parasite
vaccines (e.g., LdCen−/−)f o rab r i e fp e r i o da n di m m u n e
responses (Th1) potentially correlating with protection can
be analyzed.
7.2. Route of Administration and Mode of Virulent Challenge
for Genetically Altered Live-Attenuated Vaccines. Studies to
date with genetically targeted live-attenuated visceral Leish-
mania have primarily delivered the vaccine parasites intra-
venously [53]. If the vaccines are to be developed for human
use, more acceptable routes of injection such as intramus-
cular, subcutaneous, or intradermal must be optimized. The
intradermal infection route has been studied extensively for
cutaneous Leishmania [128]; visceralization of L. donovani
has been demonstrated after intradermal injection [129]a n d
is being further investigated by our laboratory and others
as a route of attenuated parasite vaccine administration.
Subcutaneousinjectionof L.chagasi-attenuatedparasiteshas
been tested but failed to protect [130], though the nature
of the vaccine strain, not the route of injection may be the
causeof protection failure. As the attenuated parasite vaccine
candidates are evaluated in larger animal models, these more
favorable routes of administration will be tested.
Theeﬃcacyofavaccineofanytypeisﬁnallyjudgedbyits
ability to protect recipients from natural infection. For leish-
maniasis, this is a sand ﬂy bite that delivers approximately
1,000 metacyclic promastigotes in the context of sand ﬂy
saliva, which is a potent modulator of the infection process
[131, 132]. The traditional challenge models for visceral
leishmaniasis are intravenous injection in the BALB/c mouse
and intra cardiac injection of the hamster utilizing millions
of stationary phase cultured virulent promastigotes- or
spleen-derived amastigotes. The metacyclogenesis in culture
is only partial; so stationary phase promastigotes is an
imperfect model of the natural infection, but ﬁcoll gradient
separation of metacyclics improves the model [53]. The
advantage of these challenge models is that they are well
characterized, the disease outcome in a na¨ ıve animal is
documented, and comparison of a current vaccine under
evaluation can be made to earlier vaccine candidates. These
models can be improved by dose modulation. A suﬃciently
virulent L. donovani strain that is maintained by continuous
passage in hamsters will produce a robust infection with as
little as 105 stationary promastigotes from the ﬁrst culture
passage after harvesting from a hamster spleen. Low dose
needle injection intradermally in the ear is a challenge
model much closer to the natural infection; however, the
uncertainties of visceralization and the long delay to disease
symptoms may not be worth overcoming, especially in the
light of recent demonstration that vaccines that protect
against needle challenge do not protect against infected sand
ﬂy bites [133]. Insectaries in which to perform Leishmania
infected sand ﬂy transmission to rodent models are not
common and are challenging to maintain. However, the
beneﬁts of evaluating candidate vaccines for eﬃcacy against
thenaturalsandﬂymode oftransmissionwillvastlyimprove
the chance of ultimate success of live-attenuated Leishmania
vaccine candidates. Towards that end, we and others have
initiated studies to develop visceralization animal models
(mice and hamsters) upon challenge with infected sand
ﬂies, which could be evaluated for the eﬃcacy of genetically
altered live-attenuated Leishmania parasites.
8. Conclusions
Unlike most other pathogens, Leishmania is never fully
cleared by the immune system, depriving researchers of
any natural correlate of immunity to mimic in designing
a preventive vaccine that seeks to achieve sterile immunity.
With vaccine candidates being tested, despite having been
made empirically, detailed understanding is needed about
the mechanisms by which the vaccines stimulate protec-
tive immunity. A methodical understanding of protective
immune responses and generation and maintenance of
the immunological memory during Leishmania infection
is needed for a sustained long-term protective response.
While developing attenuated strains of Leishmania,f o c u s
is required towards obtaining attenuation selectively at the
intracellular stage (amastigotes), while remaining nonatten-
uated as promastigotes to permit large scale cultivation for
use as vaccines. In order to enhance the potential of live
parasite vaccines, optimization of attenuation needs to be
explored, probably via a combination of gene deletions by
knocking out more than one gene in a single Leishmania
strain. There is a need to develop broadly immunogenic
vaccines that induce protection against a wide range of
Leishmaniastrainsthatarecausativeagentsofmanydiﬀerent
clinical forms of leishmaniasis. Lastly, safety of genetically
altered parasites is of paramount importance if such vaccines
are to be used in humans. Hence, studies are needed to
develop indicators of safety for such vaccine candidates.
Upon success, such approaches will be applicable to develop
live-attenuated vaccine candidates for other intracellular
pathogens like malaria and bacterial infections.
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